Martindale Pharma launches Teglutik for ALS patients

18 December 2015

Martindale Pharma has announced the launch of Teglutik for patients with amyotrophic lateral sclerosis (ALS), the most common form of motor neurone disease (MND) in the UK.

The launch represents an important development for patients with ALS, 80% of whom are unable to swallow due to dysphagia (discomfort in swallowing), which is a complication of the disease.

Riluzole is recommended by the UK's National Institute of Health and Care Excellence (NICE) and has been proven to significantly extend survival in patients with ALS. In clinical studies this extension of survival has been shown to be up to 2.8 months. However, this has been extended up to 21 months based on real world data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK